DOCSLIB.ORG

Daily Information Update – Japan Securities Inc (July 30 , 2021)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Daily Information Update – Japan Securities Inc (July 30 , 2021) th Daily Information Update – Japan Securities Inc (July 30 , 2021) July 30th, 2021 Table of content 1. Shares record four-day gains on bank, steel stocks 2. Domestic vaccines reach ever closer 3. Textilers adhering to strict measures Table Table content of 4. Vietnam-U.S. sea shipping rates soar to record highs 5. 2021 Vietnam Annual Economic Report launched 6. Country cracks on with vital public investment ambitions 7. Seven-month CPI lowest since 2016: GSO 8. DGW: Digiworld records significant growth in profit, boosted by mobile phone sales 9. HDB: HDBank finalises shareholder list to pay 25 per cent share dividend JSI Research Team 1 th Daily Information Update – Japan Securities Inc (July 30 , 2021) Market Analysis 1. Shares record four-day gains on bank, steel stocks Vietnamese shares rose for four straight days on said. Thursday, bolstered by a significant injection of cash flow into banking and steel stocks, pushing “The current trading value of VND15 trillion to up indices. VND17 trillion is more reasonable,” he said. The VN-Index on the Ho Chi Minh Stock Exchange The VN30-Index, which tracks 30 biggest stocks (HoSE) rose 1.29 per cent to close the afternoon on the southern bourse, witnessed an increase of trade at 1,293.60 points. 1.42 per cent to close Thursday at 1,427.55 points. Of the VN30 basket, 23 stocks climbed while four The southern market index has risen a total of two slid. per cent in the last four days. Banking and steel stocks attracted cash flow with The market's breadth was positive with 251 many gainers such as steel giant Hoa Phat Group stocks increasing while 134 declined. (HPG), Pomina Steel (POM), Hoa Sen Group (HSG), Nam Kim Group (NKG), Asia Commercial Bank Nearly VND16.3 trillion (US$713 million) was (ACB), Bank for Investment and Development of poured into the southern market, equivalent to a Vietnam (BID), Vietinbank (CTG), Military Bank trading volume of more than 491 million shares. (MBB), Sacombank (STB), VPBank (VPB) and Techcombank (TCB). “After a boom in the first half of 2021, market liquidity has been falling sharply since the The residential real estate group also slightly beginning of July, even as HoSE solved the rebounded from the end of the morning session. problem of system overloading,” said news site Among the gainers were Ha Do Group JSC (HDG), cafef.vn. Khang Dien House (KDH), Dat Xanh Group (DXG) and Century Land JSC (CRE). “The recent sharp decline in market liquidity may come from the fear about the complexity of the On the Ha Noi Stock Exchange (HNX), the HNX- COVID-19 pandemic. Investors tend to wait for Index also rose 1.54 per cent to 310.97 points. more positive signs before they return to the market,” it said. It had also risen 0.08 per cent to close Wednesday at 306.25 points. “Market liquidity reached VND25-30 trillion in previous months but this level of liquidity is More than 87.6 million shares were traded on the difficult to maintain for a long time,” Le Anh Tuan, northern exchange, worth VND2.2 trillion. Deputy Investment Director of Dragon Capital, JSI Research Team 2 th Daily Information Update – Japan Securities Inc (July 30 , 2021) Macro & Policies 2. Domestic vaccines reach ever closer consider granting emergency circulation license for The Ministry of Health (MoH) and the Ministry of Nano Covax,” Thuan noted. Science and Technology on July 22 held a meeting with senior health experts and scientists to check According to Nanogen, the clinical trial of Nano and review necessary data and the result of clinical Covax has to date been conducted on 13,620 trials of the Nano Covax COVID-19 vaccine for volunteers, including 60 in the first stage, 560 in the consideration of licensing for emergency use. second stage, and 13,000 in the third stage, in which 1,004 received two shots. According to professors and based on the research data, the vaccine has been assessed to reach safety “The company will continue to add and complete and create immunity, but still requires more time to the documents on the products and preclinical and assess its efficacy. clinical trials this week to report to the MoH,” said a Nanogen representative. Prof. Dr. Pham Ngoc Dinh, member of the National Ethics Council for Biomedical Research, said that Vietnam is striving to successfully produce at least the vaccine research should pay attention to design one locally-made COVID-19 vaccine in 2021 to updates, licensing with conditions, and post- ensure sufficient vaccine supply for the nationwide licensing. “If we cannot do well with the licensing vaccination campaign, which aims for 150 million with conditions, problems could emerge in the doses to be administered by April 2022, with the post-licensing,” Dinh said. goal of vaccinating over 75 per cent of the population. MoH Deputy Minister Tran Van Thuan noted, “The MoH supports and creates conditions COVID-19 According to Nanogen, it can roll out 5-10 million vaccine developers with an expectation to soon doses a month. In addition to Nano Covax, COVIVAC have Vietnamese-made vaccines to in order gain developed by the Institute of Vaccines and Medical the initiative in supply.” Biologicals is in the second phase of clinical trials. Regarding the conditions for emergency licensing, Also last week, the Russian Direct Investment Fund Thuan proposed that Nanogen, the developer of and Vabiotech, one of Vietnam's leading pharma Nano Covax, closely works with the MoH's Agency companies, announced that the first test batch of of Science, Technology and Training as well as the Russian Sputnik V vaccine was successfully research units and scientists on completing produced in Vietnam. The batch has been shipped documents on the results of the first and second to the Gamaleya Centre in Russia for quality clinical trials, and quickens the pace for results of control. the third clinical trial. With the volume, Vietnam can take initiative in the Based on these, the deputy minister urged quantity of COVID-19 vaccines, thus enabling the scientists and other experts at the National Ethics country to ease its reliance on foreign-imported Council for Biomedical Research and the Advisory vaccines. Vietnam now uses various foreign Council for the Registration of Circulation of Drugs products for the national vaccination campaign and and Medicinal Ingredients to soon take into is continuing to negotiate with international consideration proposals on emergency licensing for partners to ensure more in the fight against COVID- Nano Covax when results prove its safety and 19. efficacy. Despite making orders with overseas producers in “When getting the results of clinical trials, along the early stages of vaccine availability, the country with ideas from councils and from domestic and is still waiting for sufficient numbers. international experts – based on the pandemic situation and vaccine demand – the MoH will JSI Research Team 3 th Daily Information Update – Japan Securities Inc (July 30 , 2021) To date, Vietnam has received four types of foreign- Elsewhere, the Institute of Vaccines and Medical made vaccines. These include nearly 4.4 million Biologicals is a research and production facility for doses of AstraZeneca from the COVAX programme medical biologicals which has researched and and through purchase, along with 1.4 million doses mastered the technology of producing flu vaccines of the vaccine donated by the Japanese on chicken eggs with embryos. It is GMP-WHO government; 2,000 doses of Sputnik V donated by certified by the Ministry of Health (MoH) and is the Russian government; 500,000 doses of Vero- currently developing the COVIVAC vaccine. Cell by Sinopharm donated by China; and about 100,000 doses of the Pfizer vaccine. Vabiotech now owns and operates a system of facilities and equipment which also meets GMP- The Southeast Asian nation is awaiting the arrival WHO standards and Good Storage Practices. It not of more vaccine doses, spread out over time. In only supplies its products to the National Expanded 2021, the goal is to receive 100 million doses Programme on Immunisation in Vietnam and including 38.9 million from COVAX, 30 million of provides services to the domestic market but also AstraZeneca, and 31 million from Pfizer/BioNTech. exports to a number of countries around the world. Currently, Vietnam has four manufacturers Meanwhile, the MoH's Centre for Research and researching COVID-19 vaccines in different Production of Vaccines and Medical Biologicals technological directions. (Polyvac) has discussed with Russian partners about coordination in research, production, import, Nanogen Pharmaceutical Biotechnology JSC is and distribution of the Sputnik V vaccine in collaborating with the Military Medical Academy to Vietnam. In December 2020, Polyvac signed a develop NanoCovax. This was the first domestic confidentiality agreement with Russia's RDIF for enterprise selected to test for a vaccine in Vietnam. the purposes of manufacturing and distributing Sputnik V in this country. 3. Textilers adhering to strict measures Century Synthetic Fibre Corporation (CSF), which immediately meet the requirements are engages in the manufacture and sale of draw- temporarily delaying shipment,” she said. textured yarn products, is still in operation under the “three on the spot” model. Under the model, Meanwhile, Thanh Cong Textile Garment enterprises can remain open if they can offer meals Investment Trading JSC generated $81.1 million in and a space to rest and sleep for employees, as revenues and $5 million in after-tax profits in the requested by Ho Chi Minh City authorities. first half, up 11 and 4.3 per cent, respectively, over the same period last year. In the first half of 2021, CSF recorded positive results with net revenues of more than $43.39 However, the company is struggling with the million and after-tax profit of $6.11 million, an outbreak in Ho Chi Minh City.
Load more

Recommended publications
  • Progress in the Development of Potential Therapeutics and Vaccines Against COVID-19 Pandemic
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 5 Issue 7 July 2021 Review Article Progress in the Development of Potential Therapeutics and Vaccines against COVID-19 Pandemic Abhishek Kumar Yadav, Shubham Kumar and Vikramdeep Monga* Received: May 02, 2021 Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, Published: June 09, 2021 India © All rights are reserved by Vikramdeep *Corresponding Author: Vikramdeep Monga, Department of Pharmaceutical Monga., et al. Chemistry, ISF College of Pharmacy, Moga, Punjab, India. Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 or coronavirus disease 2019 and the same has been declared as a global pandemic by WHO which marked the third introduction of a virulent coronavirus into human society. This a threat to human life worldwide. Considerable efforts have been made for developing effective and safe drugs and vaccines against is a highly pathogenic human coronavirus in which pneumonia of unknown origin was identified in China in December 2019 and is SARS-CoV-2. The current situation and progress in the development of various therapeutic candidates including vaccines in preclini- cal and clinical studies have been described in the manuscript. Until now, many people have been infected with this lethal virus, and a lot of people have died from this COVID-19. This viral disease spreads by coming in contact with an infected person. Understand- ing of SARS-CoV-2 is growing in relation to its epidemiology, virology, and clinical management strategies. Till date, very few drugs or vaccines have been developed or approved for the treatment of this deadly disease of COVID-19 and many candidates are under the clinical development pipeline.
    [Show full text]
  • En Este Número
    Boletín Científico No. 18 (1-10 julio/2021) EN ESTE NÚMERO VacCiencia es una publicación dirigida a Resumen de candidatos vacu- investigadores y especialistas dedicados a nales contra la COVID-19 ba- la vacunología y temas afines, con el ob- sadas en la plataforma de sub- jetivo de serle útil. Usted puede realizar unidad proteica en desarrollo a sugerencias sobre los contenidos y de es- nivel mundial. (segunda parte) ta forma crear una retroalimentación Artículos científicos más que nos permita acercarnos más a sus recientes de Medline sobre necesidades de información. vacunas. Patentes más recientes en Patentscope sobre vacunas. Patentes más recientes en USPTO sobre vacunas. 1| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS Resumen de vacunas contra la COVID-19 basadas en la plataforma de subunidad proteica en desarrollo a nivel mundial (segunda parte) Las vacunas de subunidades antigénicas son aquellas en las que solamente se utilizan los fragmentos específicos (llamados «subunidades antigénicas») del virus o la bacteria que es indispensable que el sistema inmunitario reconozca. Las subunidades antigénicas suelen ser proteínas o hidratos de carbono. La mayoría de las vacunas que figuran en los calendarios de vacunación infantil son de este tipo y protegen a las personas de enfermedades como la tos ferina, el tétanos, la difteria y la meningitis meningocócica. Este tipo de vacunas solo incluye las partes del microorganismo que mejor estimulan al sistema inmunitario. En el caso de las desarrolladas contra la COVID-19 contienen generalmente, la proteína S o fragmentos de la misma como el Dominio de Unión al Receptor (RBD, por sus siglas en inglés).
    [Show full text]
  • INTERNATIONAL STUDENT COVID VACCINE LIST and COMMUNICATION Dear International Student
    INTERNATIONAL STUDENT COVID VACCINE LIST and COMMUNICATION Dear International Student We have provided a list of Selected Countries to help you find the COVID-19 vaccine you may have already received. Please see the “WHO” list below to find your COVID-19 vaccine, and if it has been APPROVED. And please upload your record following these directions: https://youtu.be/wvBGeRqIMHc If you see that your vaccine HAS NOT yet been approved by “WHO”, you may be required to receive an approved COVID-19 vaccine and upload those records to meet UC campus policy and requirements. Many US Airports are now providing COVID-19 vaccine on-site. Here is a list of several California Airports that you may arriving where you may receive a vaccine IMMEDIATELY upon your entry into the U.S. LAX – Los Angeles https://www.flylax.com/TravelSafely SNA – Orange County https://hoagurgentcare.com/airport/ SFO – San Francisco https://www.flysfo.com/travel-well/vaccination-site-sfo If you have any additional questions or concerns, please call (949)824-2300 for support. THANK YOU for helping to ensure UCI continues to be a SAFE and HEALTHY Campus! Dr Chang INDIA SOUTH KOREA TAIWAN INDONESIA VIETNAM JAPAN Vaccine Vaccine Vaccine Vaccine Vaccine Vaccine Oxford–AstraZeneca Oxford-AstraZeneca Sinovac Sputnik V Pfizer–BioNTech Covishield Pfizer–BioNTech Oxford–AstraZeneca Oxford–AstraZeneca Sinopharm Janssen Sinopharm Moderna Pfizer–BioNTech Moderna Pfizer–BioNTech Moderna Moderna Covaxin Novavax Moderna Johnson & Johnson Oxford–AstraZeneca Sputnik V Novavax Nanocovax Johnson & Johnson Sputnik V COVIVAC Sputnik V CanSino Vabiotech MVC-COV1901 ZyCoV-D Corbevax Covovax .
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 7 Giugno 2021
    Coronavirus: quello che c’è da sapere – 7 giugno 2021 Sommario Quando è iniziata l’epidemia? ...................................................................2 Come viene diagnosticata la malattia Covid-19? ...................................23 Quando è arrivata in Italia? .......................................................................2 Che cosa sono i test sierologici? a cosa servono? ................................25 A cosa è dovuta l’infezione? .....................................................................2 Chi viene colpito dalla malattia Covid-19? ............................................25 Quanto è diffusa l’epidemia? ....................................................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................25 Che cosa sono i coronavirus? ...................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....29 Qual è l’origine del virus? .........................................................................4 Il virus può mutare? ..................................................................................4 Esiste un vaccino? ...................................................................................31 Come si trasmette l’infezione? .................................................................9 Quali sono le terapie disponibili?............................................................46 I bambini sono più soggetti all’infezione? .............................................13
    [Show full text]
  • Building Visualizations to Uncover Insights in Clinical Trial and Pipeline Data
    Building visualizations to uncover insights in clinical trial and pipeline data: a COVID-19 vaccine case study Matt Eberle, Lead Developer, Analytics and Custom Solutions, BizInt Solutions, Inc. Diane Webb, President and Co-Founder, BizInt Solutions, Inc. Wednesday, March 24, 2021, 2:00 pm ET This session will start momentarily…. Webinar Host Susie Corbett PHT Chair Pharmaceutical & Health Technology Community https://connect.sla.org/pht/home Matt Eberle Lead Developer, Analytics and Custom Solutions, BizInt Solutions, Inc. [email protected] Following over ten years of experience at Wyeth, Pfizer and Sunovion as a Senior Information Scientist and Pharmaceutical Information Analyst, since 2013 Matt has helped BizInt customers use the BizInt Smart Charts and VantagePoint tools to create new solutions to address their challenges and problems. Matt lives outside Boston, MA. Diane Webb President and Co-Founder, BizInt Solutions, Inc. [email protected] Diane has over 30 years of experience managing the development of software tools to analyze and present competitive intelligence information, with a focus on drug pipeline, clinical trial and patent data. In 1996 Diane and John Willmore started BizInt Solutions to develop and market the BizInt Smart Charts product family. Diane & John live near Seattle, WA, with their current pack of four longhaired dachshunds. Building visualizations to uncover insights in clinical trial and pipeline data: a COVID-19 vaccine case study Part I: Dashboard visualizations and initial challenges PHT Pharma
    [Show full text]
  • Impfstoffkandidaten Gegen SARS-Cov-2, Die Sich Aktuell In
    Impfstoffkandidaten gegen SARS-CoV-2, die sich aktuell in klinischer Prüfung befinden (Vereinfachte Übersicht, kein Anspruch auf Vollständigkeit, alle Angaben ohne Gewähr; Stand: 12.03.2021; die Reihenfolge der Darstellung wurde der Abbildung Strategien der SARS-CoV-2- Impfstoffentwicklung angeglichen sowie eine weitere Kategorie hinzugefügt; inhaltliche Änderungen im Vergleich zur Vorversion sind farblich gekennzeichnet) IMPFSTOFF-PLATTFORM/- ENTWICKLER KLINISCHE STUDIEN ART (HAUPTSITZ) (STUDIENORT)* VIRUSBASIERTE IMPFSTOFFE Inaktivierter Virusimpfstoff Wuhan Institute of Biological Phase 1/2 (China) (SARS-CoV-2) Products/Sinopharm (China) Phase 3 (UAE) Phase 3 (Marokko) Phase 3 (Peru) Phase 3 (Bahrain, Ägypten, Jordanien, UAE) Inaktivierter Virusimpfstoff Beijing Institute of Biological Phase 1/2 (China) BBIBP-CorV (SARS-CoV-2) Products/Sinopharm (China) Phase 3 (UAE) Phase 3 (Argentinien) Phase 3 (Bahrain, Ägypten, Jordanien, UAE) Inaktivierter Virusimpfstoff Sinovac Phase 1/2 (China) CoronaVac (China) Phase 1/2 (China) (SARS-CoV-2) Phase 1/2 (China) Phase 2 (Brasilien, immunsupprimierte Patienten) Phase 3 (Brasilien) Phase 3 (Indonesien) Phase 3 (Türkei) Phase 3 (China) Phase 3 (Chile) Phase 4 (Brasilien; Rekru- tierung noch nicht begonnen) Phase 4 (Brasilien) Phase 4 (Hong Kong, Patienten mit chron. Lebererkrankungen; Rekrutierung noch nicht begonnen) Inaktivierter Virusimpfstoff Institute of Medical Biology, Phase 1 (China) (SARS-CoV-2) Chinese Academy of Medical Phase 1/2 (China) Sciences (China) Nationale Lenkungsgruppe Impfen,
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 12 Agosto 2021
    Coronavirus: quello che c’è da sapere – 12 agosto 2021 Sommario Quando è iniziata l’epidemia? ......................................2 Che cosa sono i test sierologici? a cosa servono? ................................26 Quando è arrivata in Italia? ..........................................2 Chi viene colpito dalla malattia Covid-19? ............................................27 A cosa è dovuta l’infezione? .........................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................27 Quanto è diffusa l’epidemia? ....................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....31 Che cosa sono i coronavirus? ...................................................................2 Qual è l’origine del virus? .........................................................................4 Il virus può diventare endemico?............................................................33 Il virus può mutare? ..................................................................................5 Esiste un vaccino? ...................................................................................33 Come si trasmette l’infezione? ...............................................................10 Quali sono le terapie disponibili?............................................................51 I bambini sono più soggetti all’infezione? .............................................15 Quali sono i rischi sanitari legati all’epidemia? .....................................64
    [Show full text]
  • Coronavirus Vaccine Tracker
    https://nyti.ms/2MHNdRL U.S.A. World Health Coronavirus Vaccine Tracker By Carl Zimmer, Jonathan Corum and Sui-Lee Wee Updated April 5, 2021 PHASE 1 PHASE 2 PHASE 3 AUTHORIZED APPROVED ABANDONED 50 35 23 5 8 4 Vaccines Vaccines Vaccines Vaccines Vaccines Vaccines testing safety in expanded in large-scale in early or approved abandoned and dosage safety trials efficacy tests limited use for full use after trials Vaccines typically require years of research and testing before reaching the clinic, but in 2020, scientists embarked on a race to produce safe and effective coronavirus vaccines in record time. Researchers are currently testing 86 vaccines in clinical trials on humans, and 23 have reached the final stages of testing. At least 77 preclinical vaccines are under active investigation in animals. New additions and recent updates April 5 The Walter Reed Army Institute of Research enters Phase 1. April 5 Japanʼs KM Biologics begins Phase 1/2. April 2 Franceʼs OSE Immunotherapeutics enters Phase 1. March 31 The Pfizer-BioNTech vaccine is highly effective in adolescents. March 31 Some Johnson & Johnson doses are delayed by a U.S. factory mix-up. March 30 Chinaʼs Jiangsu Rec-Biotechnology enters Phase 1. March 27 Turkeyʼs Middle East Technical and Bilkent University begin Phase 1. March 25 A vaccine from Chinaʼs Zhongyianke Biotech enters Phase 2. March 23 U.S. officials question the completeness of AstraZenecaʼs trial results. March 23 Daiichi Sankyo and the University of Tokyo enter Phase 1/2. March 22 AstraZenecaʼs vaccine is found to be 79% effective in a large U.S.
    [Show full text]
  • Covid-19 Under Democracy and Autocracy
    © Rutgers, The State University of New Jersey (New Brunswick) This publication is the work of the Spring 2021 Capstone class of the United Nations and Global Policy Studies Master of Arts program (UNMA), Political Science Department, Rutgers University (New Brunswick) June 2021 Application for permission to reproduce or translate all or any part of this publication should be made to: UNMA Secretariat Hickman Hall 89 George Street New Brunswick, NJ 08901 Email: [email protected] Title: Covid-19 Under Democracy and Autocracy Editor: Dr. Roland Rich Cover Design: Ian DeFalco Layout: Camilla Bober ISBN 978-0-578-92527-1 CONTENTS Contributors 1 Chapter 1 A Project is Born 4 Roland Rich Chapter 2 Australia’s Covid-19 Response: 10 The Achilles Heel Shahinaz Abdelhamid Chapter 3 Brazil: Negligence and Populism during 34 a Global Health Crisis Gabriela Casco Chapter 4 Cuba’s Vaunted Medical System Faces Covid-19 54 Javier Nino Chapter 5 Federalism, the EU, and Human Rights 68 in Germany under COVID-19 Camilla Bober Chapter 6 Russia: A Contest between Science and Denial 94 Amar Wason Chapter 7 South Africa Faces Covid-19 116 Delaney Charydczak Chapter 8 Taiwan: A Near Perfect Response 128 to the Coronavirus Pandemic Ryan Prieto Chapter 9 The Impact of Covid-19 on Elections 148 in Uganda Susan Ombwayo Chapter 10 The United Kingdom: Covid-19 162 and the Decay of Democracy Arsanious Hanna Chapter 11 Vietnam: Looking beyond Regime Type 182 Daphnée A.M. Fleurant Chapter 12 Conclusions, Constatations and Concerns 196 Roland Rich Bibliography 224 1 CONTRIBUTORS Shahinaz Abdelhamid received her B.S.
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 19 Luglio 2021
    Coronavirus: quello che c’è da sapere – 19 luglio 2021 Sommario Quando è iniziata l’epidemia? ......................................2 Che cosa sono i test sierologici? a cosa servono? ................................26 Quando è arrivata in Italia? ..........................................2 Chi viene colpito dalla malattia Covid-19? ............................................26 A cosa è dovuta l’infezione? .........................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................26 Quanto è diffusa l’epidemia? ....................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....31 Che cosa sono i coronavirus? ...................................................................2 Qual è l’origine del virus? .........................................................................4 Il virus può diventare endemico?............................................................32 Il virus può mutare? ..................................................................................4 Esiste un vaccino? ...................................................................................33 Come si trasmette l’infezione? ...............................................................10 Quali sono le terapie disponibili?............................................................48 I bambini sono più soggetti all’infezione? .............................................14 Quali sono i rischi sanitari legati all’epidemia? .....................................60
    [Show full text]
  • Vaccines and Vaccinations in Southeast Asia's Fight Against
    ISSUE: 2021 No. 58 ISSN 2335-6677 RESEARCHERS AT ISEAS – YUSOF ISHAK INSTITUTE ANALYSE CURRENT EVENTS Singapore | 29 April 2021 Vaccines and Vaccinations in Southeast Asia’s Fight against Covid-19 Kevin S.Y. Tan and Grace Lim* Southeast Asia has made some headway in its collective response towards Covid-19 for prevention and detection, and the next step for the region to take is to progress towards vaccine independence. In this picture, vials of the CoronaVac vaccine, developed by China's Sinovac firm, are displayed in Bangkok on February 24, 2021, as the first batch of vaccines to battle the Covid-19 coronavirus arrive in the country. Photo: Lillian SUWANRUMPHA, AFP. *Kevin S.Y. Tan is Visiting Senior Fellow at the ISEAS – Yusof Ishak Institute and Adjunct Faculty at the School of Global Studies, Thammasat University. Grace Lim is a final year economics and management major at the University of London. 1 ISSUE: 2021 No. 58 ISSN 2335-6677 EXECUTIVE SUMMARY • Vaccines are now a vital component for all countries to turn the tide in the Covid-19 pandemic. • Partly due to vaccine nationalism, questions and issues surround the reliable supply of vaccines to Southeast Asia and the eventual normalisation of travel. • Vaccine diplomacy by growing vaccine powers such as China help address supply gaps in Southeast Asia, but come at the cost of increased dependency. • Southeast Asian states, through the support of ASEAN, need to enable multilateral recognition of vaccinations to restore travel and to work towards vaccine independence to avoid potential geopolitical vulnerability. 2 ISSUE: 2021 No.
    [Show full text]
  • Good Morning Vietnam
    March 24, 2021 Good Morning Vietnam To subscribe to our report, please contact us at [email protected] Market performance VIETNAM STOCK MARKET Last trade 1D (%) 1M (%) 1Y (%) VN-INDEX 1,183.45 -0.92 1.85 79.53 Banks fell, market plunged HNX 272.34 -0.91 14.48 180.91 Vietnam stock market decreased significantly as most of major stocks went down. VN-Index UPCOM 81.14 -0.16 6.46 67.27 dropped right at the start combined with increasing volume that the loss widened during MSCI EM 1,323.77 -0.94 -3.85 65.13 the morning without any recovery signal. In the afternoon, the index moved sideways and NIKKEI 28,783.46 -0.73 -2.99 59.09 could not recover as overload problem hindered buying forces. At last, the index closed at HANG SENG 28,497.38 -1.34 -4.11 25.74 1,183.45 points, lost 10.98 points (equivalent to -0.92% DoD). As usual, the trading volume KOSPI 2,989.27 -0.51 -0.19 85.67 and value maintained at high level of 683.7mn shares and VND15,415bn, respectively. FTSE 6,699.19 -0.40 0.60 23.01 Banking and Real Estate stocks decline was the major pressure of the market: VCB (-1.24%), S&P 500 3,910.52 -0.76 -0.38 59.79 BID (-2.13%), TCB (-2.06%), VIC (-0.75%), CTG (-1.46%), VHM (-0.60%). NASDAQ 13,227.70 -1.12 -2.72 78.32 Overseas investors recorded a net-selling worth of VND288.24bn on HOSE which marked Valuation their 1-month consecutive selling.
    [Show full text]